Goch, July 4, 2018 – DFE Pharma, a global excipient supplier servicing the pharmaceutical industry, has successfully optimized its supply chain of pharmaceutical excipients further. The company has invested heavily in capacity expansion at their factories to meet the global demand for high quality excipients, namely pharmaceutical grade Lactose and Microcrystalline Cellulose (MCC).
The company’s focus is on innovation and growth, with expanding technical support and supply initiatives, including major investments in the production and warehouse facilities in Nörten-Hardenberg (Germany), Cuddalore/Nagpur (India), and Veghel (The Netherlands). The current production capacities have improved significantly for Anhydrous Lactose (SuperTab® 21AN), Spray Dried Lactose (SuperTab® 11SD), Milled and Sieved Lactose, Microcrystalline Cellulose (Pharmacel® 101, 102 and 112), and all Inhalation Grade Lactoses. We are excited that our team has further shortened our lead times and improved our reliability to meet and exceed our customers’ expectations” said Bas van Driel, CEO DFE Pharma. “All products are as you could expect from DFE Pharma of highest quality, within the agreed specs and consistency.
About DFE Pharma:
DFE Pharma is the global leader in excipient solutions. Headquartered in Goch, Germany, DFE Pharma develops, produces and markets excipients for oral solid dose and dry powder inhalation. The portfolio consists of filler/binders (Lactose, Microcrystalline Cellulose, Starches), superdisintegrants (Croscarmellose Sodium and Sodium Starch Glycolate) and carriers for inhalation (Lactose).